Published in Gene Therapy Weekly, June 23rd, 2005
According to the notice, noncompliance occurred because the company's stockholders' equity of $9,431,000 as reported on the form 10-K for the year ended December 31, 2004, was less than the $10,000,000 stockholders' equity requirement for continued listing. The company's stockholders' equity as reported on the form 10-Q for the quarter ended March 31, 2005, was $5,645,000.
On May 18, 2005, the company received notice from NASDAQ staff that the company's...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.